Efonidipine hydrochloride monoethanolate(D61160)-5mg/10mg

Efonidipine hydrochloride mono

ethanolate(D61160)-5mg/10mg
收藏
  • ¥640 - 1088
  • Bioss已认证
  • D61160
  • 2025年10月17日
    avatar
    品牌商
    9钻石会员
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 技术资料
    • 规格

      5mg/10mg

    规格:5mg产品价格:¥640.0
    规格:10mg产品价格:¥1088.0
    产品编号D61160
    英文名称Efonidipine hydrochloride monoethanolate
    中文名称盐酸依福地平一乙醇盐
    英文别名NZ-105 hydrochloride monoethanolate
    理论分子量714.185
    保存条件2-8℃
    注意事项This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
    背景资料Efonidipine hydrochloride monoethanolate (NZ-105 hydrochloride monoethanolate) is a dual T-type and L-type calcium channel blocker (CCB). IC50 value: Target: calcium channel blocker in vitro: Efonidipine and nifedipine, but not other examined CCBs, also increased the N(6), 2'-O-dibutyryladenosine 3',5'-cyclic monophosphate (dbcAMP)-induced StAR mRNA, which reflects the action of adrenocorticotropic hormone, and efonidipine and R(-)-efonidipine enhanced the dbcAMP-induced DHEA-S production in NCI-H295R adrenocortical carcinoma cells. I(Ca(T)) was blocked mainly by a tonic manner by nifedipine, by a use-dependent manner by mibefradil, and by a combination of both manners by efonidipine. IC50s of these Ca2+ channel antagonists to I(Ca(T)) and L-type Ca2+ channel current (I(Ca(L))) were 1.2 micromol/l and 0.14 nmol/l for nifedipine; 0.87 and 1.4 micromol/l for mibefradil, and 0.35 micromol/l and 1.8 nmol/l for efonidipine, respectively . in vivo: Twenty hypertensive patients on chronic hemodialysis were given efonidipine 20-60 mg twice daily and amlodipine 2.5-7.5 mg once daily for 12 weeks each in a random crossover manner. The average blood pressure was comparable between the efonidipine and amlodipine periods (151 + or - 15/77 + or - 8 versus 153 + or - 15/76 + or - 8 mmHg). The pulse rate did not change significantly during the administration periods. In the UM-X7.1 group, EFO treatment significantly attenuated the decrease of LVEF without affecting blood pressure compared with the vehicle group. EFO treatment decreased heart rate (by approximately 10%) in both groups

     

     

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥600
    上海莼试生物技术有限公司
    2025年07月12日询价
    ¥99
    上海鹿森生物工程有限公司
    2025年10月24日询价
    ¥99
    浙江联硕生物科技有限公司
    2025年10月24日询价
    ¥99
    上海联硕生物科技有限公司
    2025年10月24日询价
    ¥100
    上海博耀商贸有限公司
    2025年07月16日询价
    Efonidipine hydrochloride monoethanolate(D61160)-5mg/10mg
    ¥640 - 1088